Benchling: $6.1B valuation, IPO Readiness 70, Series F. R&D cloud platform for life sciences teams to design, track, and analyze experiments. Track live on The IPO Stack.
R&D cloud platform for life sciences teams to design, track, and analyze experiments.
Scores, valuations, and IPO signals for the companies that matter. 5-minute read, every Tuesday.
Top companies most likely to IPO in 2026, ranked by IPO Readiness Score.
Track Benchling IPO timeline, funding rounds, investor activity, and valuation on TechStackIPO — the pre-IPO intelligence platform.
Benchling has not announced a specific IPO date as of 2026. With an IPO Readiness Score of 70/100, the company shows strong pre-IPO signals. Subscribe to The IPO Stack newsletter for weekly updates.
Benchling is valued at $6.1B as of November 2021. This valuation is based on its most recent private funding round tracked by TechStackIPO.
Accredited investors can access Benchling shares through secondary market platforms, pre-IPO investment funds, and broker-dealer platforms that facilitate private company transactions. TechStackIPO's marketplace tracks available access options. Note: pre-IPO investments carry higher risk and limited liquidity compared to public market investing.
Benchling scores 70/100 (Grade: B) on TechStackIPO's IPO Readiness Index. The score evaluates funding scale, valuation trajectory, funding momentum, stage progression, and company maturity. Scores above 70 indicate strong near-term IPO potential.
Benchling has raised $260M in total venture capital and private equity funding, with backing from Meritech Capital, Franklin Templeton, Coatue.
Benchling's notable investors include Meritech Capital, Franklin Templeton, Coatue, Sequoia Capital, Benchmark. Full investor details, funding round history, and lead investor breakdowns are available on TechStackIPO.
Benchling is a Biotechnology company. R&D cloud platform for life sciences teams to design, track, and analyze experiments.